Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PR-171

An epoxomicin derivate with potential antineoplastic activity. PR-171 irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Carfilzomib [(2S)-N-[(S)-1-[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxopentan-2-ylcarbamoyl]-2-phenylethyl]-2-[(S)-2-(2… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2011
2011
Carfilzomib (formerly PR-171) is a novel epoxyketone-based irreversible proteasome inhibitor. In preclinical studies, carfilzomib… Expand
Is this relevant?
2010
2010
Proteasomes degrade most proteins in mammalian cells and are established targets of anti-cancer drugs. The majority of proteasome… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and structurally… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Proteasome inhibitors represent a new class of antineoplastic drugs that are considered in the treatment of haematological… Expand
Is this relevant?
2007
2007
Carfilzomib (CFZ) is a structurally- and mechanistically-novel proteasome inhibitor of peptide epoxyketone class that exhibits a… Expand
Is this relevant?
2007
2007
Introduction: Carfilzomib (CFZ) is a structurally- and mechanistically-novel proteasome inhibitor (PI) of the peptide epoxyketone… Expand
Is this relevant?
2005
2005
Recent clinical studies have identified the proteasome as an important therapeutic target for hematologic malignances. The… Expand
Is this relevant?